Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment
Clinical role
Measurement or quantification
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: DICOM brain 3D T1-weighted MRI and amyloid PET or FDG PET
Who uses it?Intended users: Medical professionals interpreting and quantitatively assessing brain MRI and PET
What does the software produce?Output: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports
What is its most important limitation?Key limitation: Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.
Clinical takeaway. Clinical role: Brain MRI/PET registration, segmentation and quantitative PET assessment
Evidence takeaway. Evidence from the reviewed source record: Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Brain MRI/PET registration, segmentation and quantitative PET assessment
Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.
Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.
A single clinically interpretable sensitivity for the cleared multipurpose quantification workflow was not established by the reviewed summary.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
Segmentation and quantification agreement results do not establish a product-wide diagnostic specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252563 MRI segmentation validation
DesignStandalone comparison with manual segmentation by four experts
PopulationBrain T1-weighted MRI test cases
Scopeexact submission
Tested versionSCALE PET submitted in K252563; numbered release not specified
Samplen=64
IndependenceIndependence not established
K252563
Preserves the baseline 64-case study and adds separate PET/registration cohorts in evidenceSummary; cohorts must not be pooled.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM brain 3D T1-weighted MRI and amyloid PET or FDG PET
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Hosting topology, processing location and licensed workstation/server configuration were not established for a purchased US version.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-05 ·
Returned objects
Source context, not route validation: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Neurophet announced on its press page and company history page that it obtained international information security certifications ISO 27001 and ISO 27701 (Korean-language pages).
Vendor-wide
Checked 2026-10-27
Vendor statement (Korean-language press release headline and history entry on the owning domain); the press page body did not render readable text on 2026-10-27 and certificates were not read. Exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Radiological images; modality varies or is not specified in FDA list
FDA source
Exact FDA submission
Checked 2026-09-05
Existing broad catalog category retained because the controlled vocabulary has no combined MRI/PET entry. The summary specifically requires 3D T1-weighted MRI and amyloid or FDG PET; this is not an unknown input modality.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
11Source classes checked
2Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Both PubMed records name SCALE PET and are retained as family contextual studies. NCT07417540 metadata identifies a Neurophet quantitative brain PET evaluation, but live registry returned a JavaScript shell; methods, outcomes and exact version remain unverified. The current discovery snapshot contains 2 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
Reviewed product material did not establish an exact-version US license or per-analysis rate.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Neurophet AQUA reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Results were Japan or Korea coverage news and vendor pages, not US coding or payment for this product. This records what was found, not that none exists.
Deployment: Not verified - checked 2026-09-05 - Exact FDA submission
Hosting topology, processing location and licensed workstation/server configuration were not established for a purchased US version.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Tracer-specific onboarding and acceptance criteria require vendor confirmation.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Update validation and site-level tracer/registration failure monitoring remain unestablished.
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.